0001493152-21-018025.txt : 20210729 0001493152-21-018025.hdr.sgml : 20210729 20210729060437 ACCESSION NUMBER: 0001493152-21-018025 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20210729 DATE AS OF CHANGE: 20210729 EFFECTIVENESS DATE: 20210729 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CYTRX CORP CENTRAL INDEX KEY: 0000799698 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 581642750 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-408110 FILM NUMBER: 211124648 BUSINESS ADDRESS: STREET 1: 11726 SAN VICENTE BOULEVARD STREET 2: SUITE 650 CITY: LOS ANGELES STATE: CA ZIP: 90049 BUSINESS PHONE: 310-826-5648 MAIL ADDRESS: STREET 1: 11726 SAN VICENTE BOULEVARD STREET 2: SUITE 650 CITY: LOS ANGELES STATE: CA ZIP: 90049 D 1 primary_doc.xml X0708 D LIVE 0000799698 CYTRX CORP 11726 SAN VICENTE BOULEVARD SUITE 650 LOS ANGELES CA CALIFORNIA 90049 (310) 826-5648 DELAWARE None None Corporation true John Caloz 11726 San Vicente Boulevard Suite 650 Los Angeles CA CALIFORNIA 90049 Executive Officer Chief Financial Officer Steven A Kriegsman 11726 San Vicente Boulevard Suite 650 Los Angeles CA CALIFORNIA 90049 Executive Officer Director Chairman and Chief Executive Officer Louis J Ignarro 11726 San Vicente Boulevard Suite 650 Los Angeles CA CALIFORNIA 90049 Director Joel Caldwell 11726 San Vicente Boulevard Suite 650 Los Angeles CA CALIFORNIA 90049 Director Pharmaceuticals Decline to Disclose 06b false 2021-07-13 true true true true false 0 H.C. Wainwright & Co., LLC 375 None None 430 PARK AVENUE 4TH FLOOR NEW YORK NY NEW YORK 10022 NY NEW YORK false 18240000 8240000 10000000 Represents (ii) 8,240 shares of Series C 10.00% Convertible Preferred Stock at a price of $1,000 per share, and (ii) preferred investment options to purchase up to an aggregate of 11,363,637 shares of common stock at an exercise price of $0.88 per share. false 1 681600 0 Consists of: $600,000 cash fee (6% of the aggregate gross proceeds), $75,000 in reimbursable non-accountable expenses, $6,600 in escrow fees and $600,000, the maximum additional cash fee payable to the Agent, subject to the exercise of POI for cash. 0 false CYTRX CORP /s/ John Caloz John Caloz Chief Financial Officer 2021-07-29